• In early August 2026, Oscar Health, Inc. reported that it moved from a net loss to net income of US$361.81 million in the second quarter and US$1.04 billion for the first half, with earnings per share turning positive on both a basic and diluted basis.
• Alongside this shift to profitability, Oscar Health raised its 2026 guidance for total revenue to US$18.7–US$19.0 billion and for earnings from operations to US$500–US$700 million, underscoring how pricing discipline and technology-driven efficiencies are reshaping its financial profile.
• Now we’ll examine how Oscar Health’s upgraded 2026 earnings from operations guidance could influence its previously cautious investment narrative.

Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.

Oscar Health Investment Narrative Recap

To own Oscar Health today, you need to believe its technology, pricing discipline, and ACA-focused model can sustain profitable growth while keeping medical costs under control. The key near term catalyst is whether the company can deliver on its sharply higher 2026 operating earnings guidance, while the biggest current risk is that utilization, risk adjustment, or churn pressures could erode margins again. The latest results and guidance upgrade directly sharpen both the opportunity and that risk.

The most relevant update is Oscar Health’s decision on 6 August 2026 to nearly double its 2026 earnings from operations guidance to US$500–US$700 million, while reaffirming revenue of US$18.7–US$19.0 billion. For anyone watching catalysts, this raises the bar for execution on pricing, cost control, and membership quality, making each upcoming quarter a more important test of whether the recent profitability can hold up under real world medical cost trends.

Yet against this stronger outlook, the risk that medical costs, risk adjustment, and churn could again pressure margins is something investors should be aware of as they consider...

Oscar Health's narrative projects $23.8 billion revenue and $998.5 million earnings by 2029. This requires 21.4% yearly revenue growth and about a $1.0 billion earnings increase from -$39.4 million today.

Uncover how Oscar Health's forecasts yield a $24.20 fair value, a 26% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming only about US$18.9 billion of revenue and US$813.7 million of earnings by 2029, so this latest profitability surprise may force a rethink of both their downside risks and upside catalysts.

Explore 8 other fair value estimates on Oscar Health - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Oscar Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Oscar Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oscar Health's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.